奎硫平与利培酮治疗慢性精神分裂症研究  

A study of quetiapine and risperidone in treatment of chronic schizophrenia

作　　者：王翠敏[1] 许小梅[1] 霍绪平[1] 

机构地区：[1]河北省荣军医院,保定071000

出　　处：《临床精神医学杂志》2007年第4期265-266,共2页Journal of Clinical Psychiatry

摘　　要：目的:比较奎硫平与利培酮对慢性精神分裂症的疗效和安全性。方法:将70例慢性精神分裂症患者随机分为两组,分别选用奎硫平或利培酮治疗,疗程8周。采用阳性与阴性症状量表(PANSS)及治疗中出现的症状量表(TESS)评定疗效和不良反应。结果:2药对慢性精神分裂症的疗效相当,不良反应发生率及严重程度均相仿。结论:奎硫平与利培酮治疗慢性精神分裂症均有肯定的疗效,且安全性高。Objective：To compare the efficacy and safety between quetiapine and risperidone in the treatment of chronic schizophrenia. Method： Seventy patients with chronic schizophrenia were randomly divided into two groups receiving quetiapine or risperidone treatment respectively. The period of treatment were 8 weeks. The positive and negative symptom scale （PANSS） and treatment emergent symptom scale （TESS） were used to evaluate the efficacy and side effects. Results： Both groups had similar efficacy and severity of side effects. Conclusion： Both quetiapine and risperidone have definite effect and rather high safety in the treatment of chronic schizophrenia.

关 键 词：精神分裂症 奎硫平 利培酮 

分 类 号：R749.3[医药卫生—神经病学与精神病学]